Lys375
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Mono-methylation Site Page: > Lys375  -  PIP4K2A (human)

Site Information
AMBIGUOUS SITES: PIP4K2B (human): , PIP4K2C (human):
KKAAHAAktVKHGAG   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 40251707
Available spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 )
Disease tissue studied:
lung cancer ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 ) , non-small cell lung cancer ( 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 ) , non-small cell lung adenocarcinoma ( 3 , 4 , 6 , 7 , 8 ) , non-small cell large cell lung carcinoma ( 4 , 6 ) , non-small cell squamous cell lung carcinoma ( 10 ) , small-cell lung cancer ( 1 , 2 )
Relevant cell line - cell type - tissue:

References 

1

Rikova K (2013) CST Curation Set: 20125; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info

2

Rikova K (2013) CST Curation Set: 20126; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info

3

Rikova K (2013) CST Curation Set: 20127; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info

4

Rikova K (2013) CST Curation Set: 20128; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info

5

Rikova K (2013) CST Curation Set: 20129; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info

6

Rikova K (2013) CST Curation Set: 20131; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info

7

Rikova K (2013) CST Curation Set: 20132; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info

8

Rikova K (2013) CST Curation Set: 20133; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info

9

Rikova K (2012) CST Curation Set: 16504; Year: 2012; Biosample/Treatment: cell line, A549/iressa, gleevec, crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info

10

Rikova K (2012) CST Curation Set: 16503; Year: 2012; Biosample/Treatment: cell line, H1703/gleevec; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info